Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin

References

• Hepatitis C fact sheetGenevaWorld Health Organization URL: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 13, 2009.
   Google Scholar
• BenvegnùLGiosMBoccatoSAlbertiANatural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complicationsGut200453574474915082595
   PubMed Web of Science ®Google Scholar
• NiederauCLangeSHeintgesTPrognosis of chronic hepatitis C: results of a large, prospective cohort studyHepatology1998286168716959828236
   PubMed Web of Science ®Google Scholar
• Cdc.gov [homepage on the Internet]Centers for Disease Control and Prevention (US). Division of Viral Hepatitis. US disease burden data: 1980–2003 URL: http://www.cdc.gov.myaccess.library.utoronto.ca/ncidod/diseases/hepatitis/resource/PDFs/disease_burden2004.pdf. Accessed July 18, 2008.
   Google Scholar
• MühlbergerNSchwarzerRLettmeierBSroczynskiGZeuzemSSiebertUHCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityBMC Public Health200922934
   Google Scholar
• MukherjeeSSorrellMFControversies in Liver Transplantation for Hepatitis CGastroenterology200813461777178818471554
   PubMed Web of Science ®Google Scholar
• PrietoMBerenguerMRimolaALiver transplantation in hepatitis C. A Spanish multicentre experienceEur J Gastroenterol Hepatol19981097717769831272
   PubMedGoogle Scholar
• WiseMBialekSFinelliLBellBPSorvilloFChanging trends in hepatitis C-related mortality in the United States, 1995–2004Hepatology20084741128113518318441
   PubMed Web of Science ®Google Scholar
• DavisGLAlbrightJECookSFRosenbergDMProjecting future complications of chronic hepatitis C in the United StatesLiver Transpl20039433133812682882
   PubMed Web of Science ®Google Scholar
• Deuffic-BurbanSWongJBValleronAJCostagliolaDDelfraissyJFPoynardTComparing the public health burden of chronic hepatitis C and HIV infection in FranceJ Hepatol200440231932614739105
   PubMed Web of Science ®Google Scholar
• SypsaVTouloumiGPapatheodoridisGVFuture trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatmentsJ Viral Hepat200512554355016108772
   PubMed Web of Science ®Google Scholar
• Deuffic-BurbanSPoynardTSulkowskiMSWongJBEstimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United StatesJ Viral Hepat200714210711517244250
   PubMed Web of Science ®Google Scholar
• MaylinSMartinot-PeignouxMMoucariREradication of hepatitis C virus in patients successfully treated for chronic hepatitis CGastroenterology2008135382182918593587
   PubMed Web of Science ®Google Scholar
• BrunoSStroffoliniTColomboMfor Italian Association of the Study of the Liver Disease (AISF)Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective studyHepatology200745357958717326216
   PubMed Web of Science ®Google Scholar
• VeldtBJHeathcoteEJWedemeyerHSustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosisAnn Intern Med20071471067768418025443
   PubMed Web of Science ®Google Scholar
• MalletVGilgenkrantzHSerpaggiJBrief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis CAnn Intern Med2008149639940318794559
   PubMed Web of Science ®Google Scholar
• HoofnagleJHMullenKDJonesDBTreatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary reportN Engl J Med1986315157515783097544
   PubMed Web of Science ®Google Scholar
• LinRRoachEZimmermanMStrasserSFarrellGCInterferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trialJ Hepatol1995234874968583134
   PubMed Web of Science ®Google Scholar
• PoynardTBedossaPChevallierMA comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitisN Engl J Med1995332145714627739681
   PubMed Web of Science ®Google Scholar
• McHutchisonJGGordonSCSchiffERInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl J Med199833921148514929819446
   PubMed Web of Science ®Google Scholar
• PoynardTMarcellinPLeeSSRandomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Lancet19983529138142614329807989
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trialLancet2001358928695896511583749
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• SimmondsPHolmesECChaTAClassification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 regionJ Gen Virol199374Pt 11239123998245854
   PubMedGoogle Scholar
• SimmondsPGenetic diversity and evolution of hepatitis C virus – 15 years onJ Gen Virol200485Pt 113173318815483230
   PubMed Web of Science ®Google Scholar
• ZeinNNClinical significance of hepatitis C virus genotypesClin Microbiol Rev200013222323510755999
   PubMed Web of Science ®Google Scholar
• Rubbia-BrandtLQuadriRAbidKHepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3J Hepatol200033110611510905593
   PubMed Web of Science ®Google Scholar
• HadziyannisSJSetteHJrMorganTRfor PEGASYS International Study GroupPeginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med2004140534635514996676
   PubMed Web of Science ®Google Scholar
• NeumannAULamNPDahariHDifferences in viral dynamics between genotypes 1 and 2 of hepatitis C virusJ Infect Dis20001821283510882578
   PubMedGoogle Scholar
• TsubotaAChayamaKIkedaKFactors predictive of response to interferon-alpha therapy in hepatitis C virus infectionHepatology1994195108810948175130
   PubMedGoogle Scholar
• DiodatiGBonettiPTaggerARelationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-upDig Dis Sci19943911249725027525169
   PubMedGoogle Scholar
• GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of hepatitis C: An updateHepatology20094941335137419330875
   PubMed Web of Science ®Google Scholar
• SiebertUSroczynskiGAidelsburgerPClinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelinesPharmacoeconomics200927434135419485429
   PubMedGoogle Scholar
• BergTvon WagnerMNasserSExtended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirinGastroenterology200613041086109716618403
   PubMed Web of Science ®Google Scholar
• JensenDMMorganTRMarcellinPEarly identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapyHepatology200643595496016628671
   PubMed Web of Science ®Google Scholar
• Sánchez-TapiasJMDiagoMEscartínPfor TeraViC-4 Study GroupPeginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatmentGastroenterology2006131245146016890599
   PubMedGoogle Scholar
• ZeuzemSButiMFerenciPEfficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJ Hepatol20064419710316290907
   PubMed Web of Science ®Google Scholar
• YuJWWangGQSunLJLiXGLiSCPredictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirinJ Gastroenterol Hepatol200722683283617565637
   PubMed Web of Science ®Google Scholar
• FerenciPLaferlHScherzerTMfor Austrian Hepatitis Study GroupPeginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological responseGastroenterology2008135245145818503773
   PubMed Web of Science ®Google Scholar
• MangiaAMinervaNBaccaDIndividualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trialHepatology2008471435018069698
   PubMed Web of Science ®Google Scholar
• de Segadas-SoaresJAVillela-NogueiraCAPerezRMNabucoLCBrandão-MelloCECoelhoHSIs the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?J Clin Gastroenterol200943436236619077732
   PubMedGoogle Scholar
• YuMLDaiCYHuangJFRapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trialHepatology20084761884189318508296
   PubMed Web of Science ®Google Scholar
• LiuCHLiuCJLinCLPegylated interferon-a-2a plus ribavirin for treatment-naive asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trialClin Infect Dis200847101260126918834319
   PubMed Web of Science ®Google Scholar
• DalgardOBjøroKHellumKBTreatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot studyHepatology20044061260126515558712
   PubMedGoogle Scholar
• MangiaASantoroRMinervaNPeginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3N Engl J Med2005352252609261715972867
   PubMed Web of Science ®Google Scholar
• von WagnerMHuberMBergTPeginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis CGastroenterology2005129252252716083709
   PubMed Web of Science ®Google Scholar
• ShiffmanMLSuterFBaconBRfor ACCELERATE InvestigatorsPeginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3N Engl J Med2007357212413417625124
   PubMed Web of Science ®Google Scholar
• YuMLDaiCYHuangJFA randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut200756455355916956917
   PubMed Web of Science ®Google Scholar
• LaggingMLangelandNPedersenCfor NORDynamIC Study GroupRandomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infectionHepatology20084761837184518454508
   PubMed Web of Science ®Google Scholar
• DalgardOBjøroKRing-LarsenHfor North-C GroupPegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological responseHepatology2008471354317975791
   PubMed Web of Science ®Google Scholar
• FerenciPFriedMWShiffmanMLPredicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinJ Hepatol200543342543315990196
   PubMed Web of Science ®Google Scholar
• Martinot-PeignouxMMaylinSMoucariRVirological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirinAntivir Ther200914450151119578235
   PubMed Web of Science ®Google Scholar
• DiagoMOlveiraASoláRTreatment of chronic hepatitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rateAliment Pharmacol Ther200725889990617402993
   PubMed Web of Science ®Google Scholar
• DavisGLWongJBMcHutchisonJGMannsMPHarveyJAlbrechtJEarly virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CHepatology200338364565212939591
   PubMed Web of Science ®Google Scholar
• McHutchisonJGLawitzEJShiffmanMLIDEAL Study TeamPeginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionN Engl J Med2009361658069319625712
   PubMed Web of Science ®Google Scholar
• JacobsonIMBrownRSJrFreilichBPeginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trialHepatology200746497198117894303
   PubMed Web of Science ®Google Scholar
• DhumeauxDMarcellinPLereboursETreatment of hepatitis C. The 2002 French consensusGut200352121784178714633963
   PubMedGoogle Scholar
• McCaughanGWOmataMAmarapurkarDfor Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working PartyAsian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infectionJ Gastroenterol Hepatol200722561563317444847
   PubMedGoogle Scholar
• OrlentHVrolijkJMVeldtBJSchalmSWHepatitis C 2002 guidelines: summary and annotationsScand J Gastroenterol2003Suppl 239105110
   Google Scholar
• ShermanMBainVVilleneuveJPThe management of chronic viral hepatitis: A Canadian consensus conference 2004Can J Infect Dis Med Microbiol200415631332618159509
   PubMedGoogle Scholar
• PearlmanBLEhlebenCSaifeeSTreatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow respondersHepatology20074661688169418046717
   PubMedGoogle Scholar
• ButiMLurieYZakharovaNGExtended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study [abstract]J Hepatol2009501 SupplS58
   Google Scholar
• ZeuzemSHultcrantzRBourliereMPeginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3J Hepatol200440699399915158341
   PubMed Web of Science ®Google Scholar
• WillemsBHadzyiannisSJMorganTRShould treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? [abstract]J Hepatol20072 SupplS6
   Google Scholar
• Hoffmann-La Roche; Hoffmann-La Roche (Clinical Trials, Study Director)A study of combination therapy With PEGASYS (peginterferon alfa-2a (40 kD) and Copegus (ribavirin) in patients with chronic hepatitis C genotype 2 or 3 who do not achieve a rapid viral response In: ClinicalTrialsgov [Internet]Bethesda (MD)National Library of Medicine (US)2000 - [cited 2009 Jul 28]. URL: http://clinicaltrials.gov/show/NCT00623428 NLM Identifier: NCT00623428
   Google Scholar
• KamalSMEl TawilAANakanoTPeginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological responseGut200554685886615888797
   PubMed Web of Science ®Google Scholar
• ZayadiARAttiaMBarakatEMFResponse of hepatitis C genotype-4 naive patients to 24 weeks of peginterferon-a2b/ribavirin or induction-dose interferon-a2b/ribavirin/amantadine: a non-randomized controlled studyAm J Gastroenterol2005100112447245216279899
   PubMedGoogle Scholar
• KamalSMEl KamarySSShardellMDPegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic responseHepatology20074661732174017943989
   PubMed Web of Science ®Google Scholar
• SmutsHEKannemeyerJGenotyping of hepatitis C virus in South AfricaJ Clin Microbiol199533167916817650216
   PubMed Web of Science ®Google Scholar
• Prabdial-SingNPurenAJMahlanguJBarrowPBowyerSMHepatitis C virus genotypes in two different patient cohorts in Johannesburg, South AfricaArch Virol2008153112049205818946631
   PubMedGoogle Scholar
• NguyenMHKeeffeEBChronic hepatitis C: Genotypes 4 to 9Clin Liver Dis200593411426vi16023974
   PubMedGoogle Scholar
• NguyenMHTrinhHNGarciaRNguyenGLamKDKeeffeEBHigher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirinAm J Gastroenterol200810351131113518477343
   PubMed Web of Science ®Google Scholar
• FungJLaiCLHungIChronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirinJ Infect Dis2008198680881218657036
   PubMed Web of Science ®Google Scholar
• DieperinkEWillenbringMHoSBNeuropsychiatric symptoms associated with hepatitis C and interferon alpha: A reviewAm J Psychiatry2000157686787610831463
   PubMed Web of Science ®Google Scholar
• SchreuderTCGelderblomHCWeeginkCJHigh incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infectionLiver Int2008281394618031478
   PubMed Web of Science ®Google Scholar
• DalgardOBjøroKHellumKThyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapyJ Intern Med2002251540040611982739
   PubMedGoogle Scholar
• SelmiCLleoAZuinMPoddaMRossaroLGershwinMEInterferon alpha and its contribution to autoimmunityCurr Opin Investig Drugs200675451456
   PubMedGoogle Scholar
• McHutchisonJGDusheikoGShiffmanMLTPL102357 Study GroupEltrombopag for thrombocytopenia in patients with cir rhosis associated with hepatitis CN Engl J Med2007357222227223618046027
   PubMed Web of Science ®Google Scholar
• McHutchisonJGWareJEJrBaylissMSfor Hepatitis Interventional Therapy GroupThe effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivityJ Hepatol200134114014711211891
   PubMed Web of Science ®Google Scholar
• DalgardOEgelandASkaugKVilimasKSteenTHealth-related quality of life in active injecting drug users with and without chronic hepatitis C virus infectionHepatology2004391748014752825
   PubMed Web of Science ®Google Scholar
• MuirAJBornsteinJDKillenbergPGAtlantic Coast Hepatitis Treatment GroupPeginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whitesN Engl J Med2004350222265227115163776
   PubMed Web of Science ®Google Scholar
• Rodriguez-TorresMJeffersLJSheikhMYLatino Study GroupPeginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis CN Engl J Med2009360325726719144941
   PubMed Web of Science ®Google Scholar
• YanKKGuirgisMDinhTTreatment responses in Asians and Caucasians with chronic hepatitis C infectionWorld J Gastroenterol200814213416342018528940
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature2009816 [Epub ahead of print]10.1038/nature08309
   Web of Science ®Google Scholar
• YamashitaTHashimotoSKanekoSComprehensive gene expression profile of a normal human liverBiochem Biophys Res Commun2000269111011610694486
   PubMed Web of Science ®Google Scholar
• YamashitaTHondaMTakatoriHNishinoRHoshinoNKanekoSGenome-wide transcriptome mapping analysis identifies organ-specific gene expression patterns along human chromosomesGenomics200484586787515475266
   PubMed Web of Science ®Google Scholar
• BiggerCBBraskyKMLanfordREDNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infectionJ Virol200175157059706611435586
   PubMed Web of Science ®Google Scholar
• SuAIPezackiJPWodickaLGenomic analysis of the host response to hepatitis C virus infectionProc Natl Acad Sci U S A20029924156691567412441396
   PubMed Web of Science ®Google Scholar
• AsselahTBiècheILaurendeauILiver gene expression signature of mild fibrosis in patients with chronic hepatitis CGastroenterology200512962064207516344072
   PubMedGoogle Scholar
• BiècheIAsselahTLaurendeauIMolecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infectionVirology2005332113014415661146
   PubMed Web of Science ®Google Scholar
• LauDTLuxonBAXiaoSYBeardMRLemonSMIntrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosisHepatology200542227328115986378
   PubMedGoogle Scholar
• SmithMWWaltersKAKorthMJGene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipientsGastroenterology2006130117918716401481
   PubMed Web of Science ®Google Scholar
• JiXCheungRCooperSLiQGreenbergHBHeXSInterferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis CHepatology200337361062112601359
   PubMed Web of Science ®Google Scholar
• ChenLBorozanIFeldJHepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infectionGastroenterology200512851437144415887125
   PubMed Web of Science ®Google Scholar
• HayashidaKDaibaASakaiAPretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patientsClin Gastroenterol Hepatol20053121253125916361052
   PubMed Web of Science ®Google Scholar
• FeldJJNandaSHuangYHepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseHepatology20074651548156317929300
   PubMed Web of Science ®Google Scholar
• AsselahTBiecheINarguetSLiver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CGut200857451652417895355
   PubMed Web of Science ®Google Scholar
• HwangYChenEYGuZJGenetic predisposition of responsiveness to therapy for chronic hepatitis CPharmacogenomics20067569770916886895
   PubMed Web of Science ®Google Scholar
• LinEHwangYWangSCGuZJChenEYAn artificial neural network approach to the drug efficacy of interferon treatmentsPharmacogenomics2006771017102417054412
   PubMed Web of Science ®Google Scholar
• HuangYYangHBorgBBA functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infectionProc Natl Acad Sci U S A2007104398599017215375
   PubMed Web of Science ®Google Scholar
• MorganTRLambrechtRWBonkovskyHLfor HALT-C Trial GroupDNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trialJ Hepatol200849454855618619701
   PubMedGoogle Scholar
• PersicoMCapassoMRussoRElevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis CGut200857450751517881539
   PubMed Web of Science ®Google Scholar
• WelzelTMMorganTRBonkovskyHLfor HALT-C Trial GroupVariants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trialHepatology20094961847185819434718
   PubMed Web of Science ®Google Scholar
• AsselahTBiècheISabbaghAGene expression and hepatitis C virus infectionGut200958684685819074178
   PubMed Web of Science ®Google Scholar
• WaltersKAKatzeMGUsing high-throughput genomics to study hepatitis C: what determines the outcome of infection?Antiviral Res200981319820819135090
   PubMed Web of Science ®Google Scholar
• McHutchisonJGEversonGTGordonSCPROVE1 Study TeamTelaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionN Engl J Med2009360181827183819403902
   PubMed Web of Science ®Google Scholar
• HézodeCForestierNDusheikoGPROVE2 Study TeamTelaprevir and peginterferon with or without ribavirin for chronic HCV infectionN Engl J Med2009360181839185019403903
   PubMed Web of Science ®Google Scholar
• KwoPLawitzEMcConeJHCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron™ (Peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C [abstract]J Hepatol2009501 SupplS4
   Google Scholar